» Articles » PMID: 36078156

Functional Intercellular Transmission of MiHTT Via Extracellular Vesicles: An In Vitro Proof-of-Mechanism Study

Overview
Journal Cells
Publisher MDPI
Date 2022 Sep 9
PMID 36078156
Authors
Affiliations
Soon will be listed here.
Abstract

Huntington's disease (HD) is a fatal neurodegenerative disorder caused by GAG expansion in exon 1 of the huntingtin () gene. AAV5-miHTT is an adeno-associated virus serotype 5-based vector expressing an engineered HTT-targeting microRNA (miHTT). Preclinical studies demonstrate the brain-wide spread of AAV5-miHTT following a single intrastriatal injection, which is partly mediated by neuronal transport. miHTT has been previously associated with extracellular vesicles (EVs), but whether EVs mediate the intercellular transmission of miHTT remains unknown. A contactless culture system was used to evaluate the transport of miHTT, either from a donor cell line overexpressing miHTT or AAV5-miHTT transduced neurons. Transfer of miHTT to recipient (HEK-293T, HeLa, and HD patient-derived neurons) cells was observed, which significantly reduced mRNA levels. miHTT was present in EV-enriched fractions isolated from culture media. Immunocytochemical and in situ hybridization experiments showed that the signal for miHTT and EV markers co-localized, confirming the transport of miHTT within EVs. In summary, we provide evidence that an engineered miRNA-miHTT-is loaded into EVs, transported across extracellular space, and taken up by neighboring cells, and importantly, that miHTT is active in recipient cells downregulating expression. This represents an additional mechanism contributing to the widespread biodistribution of AAV5-miHTT.

Citing Articles

Advances and Challenges in Gene Therapy for Neurodegenerative Diseases: A Systematic Review.

Garcia-Gonzalez N, Goncalves-Sanchez J, Gomez-Nieto R, Goncalves-Estella J, Lopez D Int J Mol Sci. 2024; 25(23).

PMID: 39684197 PMC: 11640776. DOI: 10.3390/ijms252312485.


Extracellular vesicles: biological mechanisms and emerging therapeutic opportunities in neurodegenerative diseases.

Wang L, Zhang X, Yang Z, Wang B, Gong H, Zhang K Transl Neurodegener. 2024; 13(1):60.

PMID: 39643909 PMC: 11622582. DOI: 10.1186/s40035-024-00453-6.


Exosomes in Vascular/Neurological Disorders and the Road Ahead.

Alzahrani F, Riza Y, Eid T, Almotairi R, Scherschinski L, Contreras J Cells. 2024; 13(8.

PMID: 38667285 PMC: 11049650. DOI: 10.3390/cells13080670.


Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases.

Xia X, Wang Y, Zheng J Transl Neurodegener. 2022; 11(1):53.

PMID: 36510311 PMC: 9743667. DOI: 10.1186/s40035-022-00330-0.

References
1.
Haery L, Deverman B, Matho K, Cetin A, Woodard K, Cepko C . Adeno-Associated Virus Technologies and Methods for Targeted Neuronal Manipulation. Front Neuroanat. 2019; 13:93. PMC: 6902037. DOI: 10.3389/fnana.2019.00093. View

2.
Evers M, Miniarikova J, Juhas S, Valles A, Bohuslavova B, Juhasova J . AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model. Mol Ther. 2018; 26(9):2163-2177. PMC: 6127509. DOI: 10.1016/j.ymthe.2018.06.021. View

3.
OBrien J, Hayder H, Zayed Y, Peng C . Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018; 9:402. PMC: 6085463. DOI: 10.3389/fendo.2018.00402. View

4.
Ross C, Tabrizi S . Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2010; 10(1):83-98. DOI: 10.1016/S1474-4422(10)70245-3. View

5.
Koppers-Lalic D, Hackenberg M, Bijnsdorp I, van Eijndhoven M, Sadek P, Sie D . Nontemplated nucleotide additions distinguish the small RNA composition in cells from exosomes. Cell Rep. 2014; 8(6):1649-1658. DOI: 10.1016/j.celrep.2014.08.027. View